Wells Fargo’s AbbVie ABBV Stock Holding History

Wells Fargo’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.94B	Sell	8,909,597 -238,169	-3%	-$52.8M	0.37%	51
2025 Q4	$2.09B	Buy	9,147,766 +20,626	+0.2%	+$4.7M	0.38%	50
2025 Q3	$2.11B	Buy	9,127,140 +84,392	+0.9%	+$17.2M	0.4%	48
2025 Q2	$1.68B	Buy	9,042,748 +118,090	+1%	+$21.9M	0.35%	63
2025 Q1	$1.87B	Sell	8,924,658 -241,475	-3%	-$46.9M	0.42%	51
2024 Q4	$1.63B	Sell	9,166,133 -7,730	-0.1%	-$1.42M	0.37%	62
2024 Q3	$1.81B	Sell	9,173,863 -165,027	-2%	-$30.8M	0.41%	58
2024 Q2	$1.6B	Buy	9,338,890 +317,245	+4%	+$52.6M	0.39%	60
2024 Q1	$1.64B	Sell	9,021,645 -100,911	-1%	-$17.4M	0.4%	63
2023 Q4	$1.41B	Sell	9,122,556 -232,584	-2%	-$33.9M	0.37%	67
2023 Q3	$1.39B	Sell	9,355,140 -235,881	-2%	-$34.6M	0.41%	62
2023 Q2	$1.29B	Sell	9,591,021 -176,663	-2%	-$25.9M	0.36%	69
2023 Q1	$1.56B	Sell	9,767,684 -95,631	-1%	-$14.6M	0.45%	55
2022 Q4	$1.59B	Buy	9,863,315 +615,919	+7%	+$94.4M	0.48%	44
2022 Q3	$1.24B	Buy	9,247,396 +13,803	+0.1%	+$1.98M	0.4%	56
2022 Q2	$1.41B	Sell	9,233,593 -860,039	-9%	-$131M	0.44%	50
2022 Q1	$1.64B	Buy	10,093,632 +352,890	+4%	+$51.3M	0.42%	48
2021 Q4	$1.32B	Sell	9,740,742 -1,795,704	-16%	-$212M	0.33%	68
2021 Q3	$1.24B	Sell	11,536,446 -318,079	-3%	-$36.3M	0.27%	73
2021 Q2	$1.34B	Buy	11,854,525 +239,340	+2%	+$27M	0.29%	64
2021 Q1	$1.26B	Buy	11,615,185 +587,452	+5%	+$62.8M	0.28%	71
2020 Q4	$1.18B	Buy	11,027,733 +599,875	+6%	+$57.6M	0.28%	71
2020 Q3	$913M	Sell	10,427,858 -758,396	-7%	-$71.4M	0.25%	89
2020 Q2	$1.1B	Buy	11,186,254 +2,023,901	+22%	+$178M	0.32%	59
2020 Q1	$698M	Buy	9,162,353 +767,834	+9%	+$65.4M	0.24%	95
2019 Q4	$743M	Sell	8,394,519 -242,157	-3%	-$20.1M	0.2%	115
2019 Q3	$654M	Sell	8,636,676 -665,544	-7%	-$45.6M	0.19%	120
2019 Q2	$676M	Sell	9,302,220 -3,727,928	-29%	-$293M	0.19%	117
2019 Q1	$1.05B	Sell	13,030,148 -298,732	-2%	-$24.4M	0.31%	63
2018 Q4	$1.23B	Buy	13,328,880 +1,272,084	+11%	+$112M	0.41%	43
2018 Q3	$1.14B	Sell	12,056,796 -185,819	-2%	-$17.6M	0.32%	62
2018 Q2	$1.13B	Sell	12,242,615 -469,679	-4%	-$45.9M	0.34%	55
2018 Q1	$1.2B	Sell	12,712,294 -1,057,383	-8%	-$116M	0.36%	50
2017 Q4	$1.33B	Buy	13,769,677 +373,224	+3%	+$35.2M	0.38%	44
2017 Q3	$1.19B	Sell	13,396,453 -598,035	-4%	-$45.5M	0.37%	48
2017 Q2	$1.01B	Buy	13,994,488 +5,497	+0%	+$370K	0.33%	57
2017 Q1	$912M	Buy	13,988,991 +784,539	+6%	+$49.3M	0.3%	65
2016 Q4	$827M	Buy	13,204,452 +809,725	+7%	+$49.4M	0.29%	67
2016 Q3	$782M	Buy	12,394,727 +310,372	+3%	+$20.1M	0.29%	66
2016 Q2	$748M	Buy	12,084,355 +254,454	+2%	+$15.5M	0.29%	69
2016 Q1	$676M	Buy	11,829,901 +1,611,691	+16%	+$89.8M	0.27%	78
2015 Q4	$605M	Sell	10,218,210 -185,094	-2%	-$10.7M	0.24%	93
2015 Q3	$566M	Sell	10,403,304 -1,726,413	-14%	-$112M	0.24%	92
2015 Q2	$815M	Buy	12,129,717 +851,999	+8%	+$55.6M	0.31%	57
2015 Q1	$660M	Sell	11,277,718 -2,915,555	-21%	-$176M	0.26%	82
2014 Q4	$929M	Sell	14,193,273 -1,158,603	-8%	-$73M	0.36%	41
2014 Q3	$887M	Buy	15,351,876 +1,022,090	+7%	+$56.7M	0.37%	40
2014 Q2	$809M	Buy	14,329,786 +95,120	+0.7%	+$4.99M	0.33%	48
2014 Q1	$732M	Buy	14,234,666 +2,325,235	+20%	+$118M	0.31%	57
2013 Q4	$629M	Buy	11,909,431 +1,245,829	+12%	+$61.2M	0.27%	76
2013 Q3	$477M	Sell	10,663,602 -14,379	-0.1%	-$637K	0.23%	100
2013 Q2	$441M	Buy	+10,677,981	New	+$467M	0.23%	95

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo's ABBV Position: Q1 2026 in Review

Wells Fargo reduced its AbbVie (ABBV) stake by 2.6% in Q1 2026, selling an estimated $52.8M and leaving 8,909,597 shares worth $1.94B. The position accounts for 0.37% of the portfolio, ranked #51.

Wells Fargo first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.11B in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Wells Fargo held 8,909,597 shares of AbbVie worth $1.94B as of Q1 2026.
Wells Fargo sold 238,169 AbbVie shares in Q1 2026, an estimated $52.8M.
AbbVie made up 0.37% of Wells Fargo's portfolio in Q1 2026, its #51 holding.
Wells Fargo first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's AbbVie position peaked at $2.11B in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.